Although having a baby can be an exciting and life-changing milestone, for some new parents, the experience can bring on intense sadness, anxiety, loneliness, and other emotions. These may be symptoms ...

Lipocine expects trial data to support a 505(b)(2) new drug application submission for LPCN 1154 in 2026.

ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient ...

When you think about postpartum depression, what image comes to mind? Likely the image is a new mom who is sad demonstrated through outward emotional expressions, such as crying. What likely did not ...

The postpartum period is often depicted as a time of overwhelming joy and bliss, but the reality for many new parents is far from that idealized image. It’s important to note first— postpartum ...

Therapy is a key part of treatment for postpartum depression (PPD). But during a time when you're likely already feeling overwhelmed and worn thin, figuring out the best type of therapy to treat your ...

Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum ...

To earn CME related to this news article, click here. February 11, 2009 — Women with higher levels of a hormone produced by the placenta midway through pregnancy appear to be at significantly ...

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat post ...